The DRIVE-SHIFT study evaluated switching to DOR/3TC/TDF in HIV patients with suppressed viral loads. The study aimed to assess the efficacy of DOR/3TC/TDF compared to continuation of current antiretroviral therapy (cART) at both 24 and 48 weeks. Results showed non-inferiority of DOR/3TC/TDF in main

1 views • 7 slides

HPTN 069/ACTG A5305 is a Phase II study evaluating the safety and tolerability of Maraviroc (MVC)-containing regimens compared to Tenofovir/emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) in at-risk women. The study involves a randomized, double-blind, placebo-controlled design with

0 views • 18 slides

Subgroup analysis from the iPrEx trial and open-label extension assessed the efficacy, drug concentrations, and adherence of TDF-FTC PrEP for transgender women assigned male at birth. Results indicate varying drug detection consistency and non-condom receptive anal intercourse among participants.

1 views • 7 slides

STAR Study compared the efficacy and safety of RPV/FTC/TDF and EFV/FTC/TDF in treatment-naive HIV patients. The study included 394 participants in each group, assessing HIV RNA suppression rates, CD4 count improvements, treatment responses, and resistance analyses up to 48 weeks. Results showed RPV/

0 views • 15 slides

In the STARTMRK study, Raltegravir (RAL) was compared to Efavirenz (EFV) in combination with TDF/FTC for the treatment of HIV. The study aimed to demonstrate non-inferiority of RAL compared to EFV in achieving HIV RNA levels below 50 c/mL. Baseline characteristics and patient disposition were assess

0 views • 12 slides

Dolutegravir (DTG) treatment has shown associations with weight gain and clinical obesity, particularly in black individuals and women. In contrast, tenofovir disoproxil fumarate (TDF) is linked to lower body weight compared to other treatments. Trials like ADVANCE and NAMSAL have provided insights

0 views • 31 slides

Study M02-418 compared once-daily (QD) and twice-daily (BID) LPV/r in combination with TDF and FTC for HIV treatment. The primary endpoint was achieving HIV RNA <50 c/mL at week 48, aiming for non-inferiority of QD vs. BID dosing. Patient characteristics, treatment response at week 48, and pharmacok

0 views • 7 slides

The comparison study explores NNRTI regimens alongside the DRIVE-AHEAD trial, focusing on DOR/3TC/TDF vs EFV-FTC/TDF. DRIVE-AHEAD assesses the efficacy and safety of DOR in ARV-naïve HIV patients, aiming for non-inferiority based on virologic response, with DOR exhibiting potential neuropsychiatric

0 views • 11 slides

Study results reveal that F/TAF provides rapid onset and longer sustained HIV protection compared to F/TDF in pre-exposure prophylaxis. The randomized noninferiority trial included 2694 participants with a primary analysis at weeks 48 and 96. Disclosure statements indicate involvement of various hea

0 views • 21 slides

Pooled data from 11 F/TDF demonstration projects involving over 6000 cisgender women over eight years examined adherence and HIV incidence. The study aimed to assess the effectiveness of F/TDF for HIV prevention in real-world settings, revealing adherence patterns in a subset of participants. This r

0 views • 16 slides

This study aims to describe real-world use patterns and HIV seroconversion rates for individuals using emtricitabine/tenofovir disoproxil fumarate (F/TDF) vs. emtricitabine/tenofovir alafenamide (F/TAF) as pre-exposure prophylaxis (PrEP) for HIV prevention. The retrospective analysis includes newly

0 views • 9 slides

Comparison of DTI protocols and measures in 317 participants revealed strong associations with age and cognitive impairment. MD and TDF-FA emerged as best measures, with robust connections to age. NODDI in advanced MRI allows for differentiation of A-beta positive and negative groups, offering great

0 views • 6 slides

This study compares the efficacy and safety of different protease inhibitors (PIs) including ATV, ATV/r, LPV/r, FPV/r, DRV/r, and SQV/r in HIV treatment. The ARTEMIS study specifically focuses on comparing DRV/r and LPV/r in combination with TDF/FTC in ARV-naive patients. Results show non-inferiorit

0 views • 12 slides

Nondumiso, a patient on TDF/FTC/EFV for a year, faces challenges with adherence despite good health and stability. With a VL of 1500, a thorough assessment is needed to address possible causes such as adherence, infections, dosing, interactions, and resistance. Follow-up testing, interventions, and

0 views • 23 slides